These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16950134

  • 21. [Fat metabolism and the liver].
    Gros H.
    Med Klin; 1973 Aug 10; 68(32):1021-4. PubMed ID: 4582296
    [No Abstract] [Full Text] [Related]

  • 22. [Lipid disorders in liver diseases].
    Studeník P.
    Vnitr Lek; 2000 Sep 10; 46(9):547-8. PubMed ID: 11344649
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, van Heek M, Hwa JJ.
    Eur J Pharmacol; 2008 Apr 14; 584(1):118-24. PubMed ID: 18329014
    [Abstract] [Full Text] [Related]

  • 31. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.
    van der Poorten D, George J.
    Clin Liver Dis; 2008 Nov 14; 12(4):805-24, ix. PubMed ID: 18984468
    [Abstract] [Full Text] [Related]

  • 32. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression.
    Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M.
    Hepatology; 2006 Mar 14; 43(3):506-14. PubMed ID: 16496325
    [Abstract] [Full Text] [Related]

  • 33. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C.
    Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E.
    Am J Gastroenterol; 2008 Jan 14; 103(1):147-53. PubMed ID: 18184121
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P, Coracina A, Cosma A, Tiengo A.
    Nutr Metab Cardiovasc Dis; 2009 May 14; 19(4):291-302. PubMed ID: 19359149
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Physiopathology of ethylic steatosis].
    Bertrand JL.
    Lyon Med; 1972 Jan 23; 227(2):123-38. PubMed ID: 4552771
    [No Abstract] [Full Text] [Related]

  • 38. Thioacetamide-induced hepatic damage in a rat nutritional model of steatohepatitis.
    Avni Y, Shirin H, Aeed H, Matas Z, Shahmurov M, Birkenfeld S, Bruck R.
    J Med; 2003 Jan 23; 34(1-6):121-37. PubMed ID: 17682318
    [Abstract] [Full Text] [Related]

  • 39. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.
    Obes Surg; 2006 Dec 23; 16(12):1584-93. PubMed ID: 17217634
    [Abstract] [Full Text] [Related]

  • 40. ER stress and lipogenesis: a slippery slope toward hepatic steatosis.
    Basseri S, Austin RC.
    Dev Cell; 2008 Dec 23; 15(6):795-6. PubMed ID: 19081067
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.